## Bac Viet Le

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/37312/publications.pdf

Version: 2024-02-01

		1307594	1474206
11	221	7	9
papers	citations	h-index	g-index
1.1	1.1	11	260
11	11	11	368
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood, 2017, 130, 2848-2859.	1.4	64
2	Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood, 2018, 132, 67-77.	1.4	54
3	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Research, 2021, 81, 5089-5101.	0.9	25
4	MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Advances, 2017, 1, 1467-1472.	5.2	23
5	TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Reports, 2020, 33, 108221.	6.4	18
6	4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. Blood Advances, 2022, 6, 1879-1894.	5.2	13
7	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia and Lymphoma, 2019, 60, 1098-1101.	1.3	12
8	PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions. Leukemia and Lymphoma, 2019, 60, 262-264.	1.3	9
9	Whole-exome sequencing identifies two novel missense mutations (p.L111P and p.R3048C) of RYR3 in a Vietnamese patient with autism spectrum disorders. Genes and Genomics, 2017, 39, 301-306.	1.4	2
10	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Blood, 2020, 136, 4-4.	1.4	1
11	PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions. Blood, 2018, 132, 3000-3000.	1.4	O